Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 890 (Olpasiran) in elevated Lipoprotein(a)
NCT03626662Phase 1Completed
- Sponsor
- Amgen
- Start
- Jul 2018
- Primary completion
- Apr 2023
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in hyperlipidemia comparing Placebo with AMG 890 (Olpasiran) (2 arms). Primary endpoint: Treatment-emergent Adverse Events at 8.54 months. Started Jul 2018; status: completed.
02
Drugs
olpasiran
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT03626662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03626662.